Praluent is a member of a new class of lipid-lowering agents known as PCSK9 inhibitors. It is self-administered as a subcutaneous injection in a single-use pre-filled pen or pre-filled syringe. It is indicated for use as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional lowering of low density lipoprotein cholesterol.
If you have a Hayes login, click here to view the full report on the Knowledge Center.